These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 11375979)

  • 81. Characterization of the 20S proteasome in human glioblastomas.
    Piccinini M; Rinaudo MT; Anselmino A; Ramondetti C; Buccinnà B; Fiano V; Ghimenti C; Schiffer D
    Anticancer Res; 2005; 25(5):3203-10. PubMed ID: 16101128
    [TBL] [Abstract][Full Text] [Related]  

  • 82. S-adenosylmethionine decarboxylase degradation by the 26 S proteasome is accelerated by substrate-mediated transamination.
    Yerlikaya A; Stanley BA
    J Biol Chem; 2004 Mar; 279(13):12469-78. PubMed ID: 14718534
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Catalytic site-specific inhibition of the 20S proteasome by 4-hydroxynonenal.
    Ferrington DA; Kapphahn RJ
    FEBS Lett; 2004 Dec; 578(3):217-23. PubMed ID: 15589823
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Differential impairment of 20S and 26S proteasome activities in human hematopoietic K562 cells during oxidative stress.
    Reinheckel T; Ullrich O; Sitte N; Grune T
    Arch Biochem Biophys; 2000 May; 377(1):65-8. PubMed ID: 10775442
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Proteolysis, free radicals, and aging.
    Szweda PA; Friguet B; Szweda LI
    Free Radic Biol Med; 2002 Jul; 33(1):29-36. PubMed ID: 12086679
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity.
    Meng L; Mohan R; Kwok BH; Elofsson M; Sin N; Crews CM
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10403-8. PubMed ID: 10468620
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Susceptibility of glucose-6-phosphate dehydrogenase modified by 4-hydroxy-2-nonenal and metal-catalyzed oxidation to proteolysis by the multicatalytic protease.
    Friguet B; Szweda LI; Stadtman ER
    Arch Biochem Biophys; 1994 May; 311(1):168-73. PubMed ID: 8185314
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Comparative resistance of the 20S and 26S proteasome to oxidative stress.
    Reinheckel T; Sitte N; Ullrich O; Kuckelkorn U; Davies KJ; Grune T
    Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):637-42. PubMed ID: 9794805
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Inhibition of the proteolytic activity of the multicatalytic proteinase complex (proteasome) by substrate-related peptidyl aldehydes.
    Vinitsky A; Cardozo C; Sepp-Lorenzino L; Michaud C; Orlowski M
    J Biol Chem; 1994 Nov; 269(47):29860-6. PubMed ID: 7961980
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Oxidized LDLs alter the activity of the ubiquitin-proteasome pathway: potential role in oxidized LDL-induced apoptosis.
    Vieira O; Escargueil-Blanc I; Jürgens G; Borner C; Almeida L; Salvayre R; Nègre-Salvayre A
    FASEB J; 2000 Mar; 14(3):532-42. PubMed ID: 10698969
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Evidence for the existence of a proteasome in Toxoplasma gondii: intracellular localization and specific peptidase activities.
    Paugam A; Creuzet C; Dupouy-Camet J; Roisin MP
    Parasite; 2001 Dec; 8(4):267-73. PubMed ID: 11802263
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Aging, lipofuscin formation, and free radical-mediated inhibition of cellular proteolytic systems.
    Szweda PA; Camouse M; Lundberg KC; Oberley TD; Szweda LI
    Ageing Res Rev; 2003 Oct; 2(4):383-405. PubMed ID: 14522242
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Decreased levels of proteasome activity and proteasome expression in aging spinal cord.
    Keller JN; Huang FF; Markesbery WR
    Neuroscience; 2000; 98(1):149-56. PubMed ID: 10858621
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits.
    Kessler BM; Tortorella D; Altun M; Kisselev AF; Fiebiger E; Hekking BG; Ploegh HL; Overkleeft HS
    Chem Biol; 2001 Sep; 8(9):913-29. PubMed ID: 11564559
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Regulatory subunit complex dissociated from 26S proteasome: isolation and characterization.
    Akaishi T; Yokosawa H; Sawada H
    Biochim Biophys Acta; 1995 Dec; 1245(3):331-8. PubMed ID: 8541309
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates.
    Rodgers KJ; Dean RT
    Int J Biochem Cell Biol; 2003 May; 35(5):716-27. PubMed ID: 12672463
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Subtypes of 20S proteasomes from skeletal muscle.
    Dahlmann B; Ruppert T; Kloetzel PM; Kuehn L
    Biochimie; 2001; 83(3-4):295-9. PubMed ID: 11295489
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20 S proteasome.
    Schmidtke G; Emch S; Groettrup M; Holzhutter HG
    J Biol Chem; 2000 Jul; 275(29):22056-63. PubMed ID: 10806206
    [TBL] [Abstract][Full Text] [Related]  

  • 99. 240-kDa proteasome inhibitor (CF-2) is identical to delta-aminolevulinic acid dehydratase.
    Guo GG; Gu M; Etlinger JD
    J Biol Chem; 1994 Apr; 269(17):12399-402. PubMed ID: 8175643
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome.
    Figueiredo-Pereira ME; Chen WE; Li J; Johdo O
    J Biol Chem; 1996 Jul; 271(28):16455-9. PubMed ID: 8663210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.